Drug Trial Radar · NCT05769868
Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
Last checked: Nov 19, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Apr 18, 2023
Primary completion
Mar 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)Government (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Instituto de Salud Carlos III
- First posted
- Mar 15, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and antineoplastic treatments.
Conditions
- Cirrhosis
- Diabetes Mellitus
- Oncologic Disorders
Interventions
Esmolol Injection [Brevibloc]Drug
Brevibloc® will be administered intravenously by infusion pump following the administration schedule: Loading dose of 500 μg/kg for 1 minute, followed by a maintenance infusion of 50 μg/kg/minute over 5 minutes. If the target response is not obtained, the loading dose is repeated and the 50 dose is increased by 50 μg/kg/minute to a maximum of 200 μg/kg/minute. The objective response to esmolol beta-blockade is defined as a 15-20% reduction in heart rate, with lower limits of 55 bpm and a systolic blood pressure not less than 90 mmHg and diastolic blood pressure not less than 50 mmHg. The perfusion is kept active while the echocardiography image acquisition is completed (approx. 15-30 min).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Left Ventricle (LV) ejection fractionTime frame: At Baseline (Day 1) until Month-24 according to cohort
- Peak measurement of global LV systolic longitudinal strainTime frame: At Baseline (Day 1) until Month-24 according to cohort
- Ejection Intraventricular Pressure Difference (EIVPD) measureTime frame: At Baseline (Day 1) until Month-24 according to cohort
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, Spain · Recruiting
Hospital Clínic de Barcelona
Barcelona, Barcelona, Spain · Not yet recruiting
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, Spain · Recruiting
Hospital Universitario La Paz
Madrid, Madrid, Spain · Recruiting
Hospital Clínico Universitario de Salamanca
Salamanca, Salamanca, Spain · Recruiting
Hospital Universitari i Politècnic La Fe
Valencia, Valencia, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.